{"filings":[{"id":116268,"accession_number":"0001437749-26-000805","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree Therapeutics President and COO Eric Curtis resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric L. Curtis resigned as President and COO effective January 5, 2026.","No successor named; CEO Jed Latkin assumes the President role.","Resignation was immediate; no reason disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132729,"accession_number":"0001437749-25-036665","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["2.03","3.02","3.01","9.01"],"status":"ready","headline":"Windtree issues $857K convertible note due 2026 to fund CommLoan acquisition advance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $857,142.86 in senior convertible notes to an institutional investor; interest 10% per annum, maturity Nov 26, 2026.","Proceeds: $450,000 advanced to CommLoan Inc. towards a planned acquisition; $150,000 retained for general corporate purposes.","Conversion price set at 90% of the lowest sale price over 20 consecutive trading days; beneficial ownership cap 4.99% (increaseable to 9.99%).","Note includes mandatory prepayment triggers: 25% of proceeds from existing stock purchase agreement at 115% premium; full repayment upon $1M+ equity financing.","Company must file resale registration statement within 45 days for shares underlying the note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132728,"accession_number":"0001437749-25-031178","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["2.03","3.02","3.01","9.01"],"status":"ready","headline":"Windtree Therapeutics issues $1.6M in senior convertible notes due 2026 with 10% interest and dilutive conversion terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.6M aggregate principal in senior convertible promissory notes due Oct 9, 2026 to institutional investors.","Notes bear 10% per annum interest, payable monthly starting Nov 5, 2025; principal and accrued interest due at maturity.","Conversion price set at 90% of lowest sale price over 20 consecutive trading days prior to conversion; subject to automatic adjustment if conversion price < 80% of market price.","Notes junior to existing June 2025 senior convertible note held by DFU, LLC.","25% of gross proceeds from Common Stock Purchase Agreement must prepay notes at 120% premium; full prepayment required upon qualified equity financing of $1M+."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132727,"accession_number":"0001437749-25-030516","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Windtree subsidiary settles real estate dispute; recovers $750k of $3M earnest money","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["WINT Real Estate LLC (Windtree subsidiary) settled dispute with TBB over $3M earnest money on a Houston property.","Settlement releases $750k to WINT; remainder to TBB; purchase agreement terminated; litigation dismissed.","Windtree had contributed $1.4M of the earnest money; net loss from deal ~$650k plus legal costs.","Mutual release of all claims related to purchase agreement, property, and litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149257,"accession_number":"0001437749-25-028578","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree Therapeutics CMO Dr. Steven Simonson resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven G. Simonson, M.D., resigned as SVP and Chief Medical Officer on Sept. 2, 2025.","Resignation effective immediately; no replacement named in the filing.","No reason for departure provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149256,"accession_number":"0001437749-25-028170","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Windtree shareholders approve 1:2-1:25 reverse split, 8x authorized share increase, all 9 proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 9 proposals passed at Aug 28 special meeting; majority of votes cast in favor.","Authorized shares increased to 1B from 125M (Proposal 7: 9.5M For, 1.2M Against).","Reverse stock split ratio of 1:2 to 1:25 approved; board has discretion on exact ratio and timing.","Shareholders approved issuances of common shares upon conversion of Series D, E preferred, notes, warrants, and ELOC.","2020 Equity Incentive Plan amended to reserve additional 2.6M shares for issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149255,"accession_number":"0001437749-25-027421","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Windtree Therapeutics receives Nasdaq delisting notice; stock to trade OTC Aug 21","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Windtree of delisting due to noncompliance with Listing Rule 5550(a)(2) (minimum bid price).","Trading on Nasdaq will be suspended at open on August 21, 2025.","Common stock expected to trade on OTC markets under symbol WINT, pending approval for OTCID tier.","Company will continue filing periodic reports with SEC; business operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149254,"accession_number":"0001437749-25-025762","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Windtree terminates SEISMiC-C study of istaroxime after 20 enrollments; cites limited resources","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Phase 2 SEISMiC-C trial (istaxime for cardiogenic SCAI Stage C) at 20 enrollments.","Decision driven by limited resources and desire to advance istaroxime into broader acute heart failure.","No safety concerns were cited as the reason for termination.","CEO Jed Latkin confirmed the termination in the 8-K filing filed August 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149253,"accession_number":"0001437749-25-024720","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Windtree reports positive istaroxime interim data in SCAI Stage C cardiogenic shock; plans global Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Interim analysis of first 20 patients in SEISMiC C Phase 2 study: no new safety signals, hemodynamic improvements consistent with prior trials.","Istaroxime was added to existing inotropes/vasopressors; no excess arrhythmias observed despite greater illness severity.","Company cites data as instrumental for moving istaroxime to a global Phase 3 program in heart failure and cardiogenic shock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149252,"accession_number":"0001437749-25-024625","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Leanne Kelly resigns from Windtree board; Andrew Kucharchuk appointed as replacement and Audit Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leanne Kelly resigned from Windtree Therapeutics board effective July 29, 2025; she had been Audit Committee chair.","Andrew Kucharchuk appointed to board effective August 3, 2025, also appointed chair of Audit Committee.","Kucharchuk is CFO of Cero Therapeutics Holdings and Chain Bridge I; previously CFO of Theralink Technologies.","No material arrangements, transactions, or compensatory grants disclosed in connection with Kucharchuk's appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149251,"accession_number":"0001437749-25-023352","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Windtree secures up to $520M for BNB crypto treasury; 99% of proceeds to buy BNB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Common Stock Purchase Agreement for up to $500M equity line; additional $20M agreement with Build and Build Corp.","99% of proceeds from both issuances allocated to acquiring BNB cryptocurrency.","ELOC requires stockholder approval to increase authorized shares before company can draw.","Issued $10M convertible promissory note as commitment consideration; 5% interest, matures April 2026.","Company shifts treasury strategy to focus on BNB, citing potential blockchain value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149250,"accession_number":"0001437749-25-022890","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["1.01","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Windtree raises up to $200M for BNB crypto treasury strategy, shifting from biotech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $60M securities purchase agreement (upsizable to $200M) led by Build and Build Corp for Series E Preferred Stock and Warrants.","Proceeds to acquire BNB token for treasury; co aims to be first NASDAQ-listed direct exposure to Binance ecosystem.","Series E convertible at $0.30/share; warrant exercise price $0.75; closing depends on stockholder approval within 120 days.","Lead investor may nominate two board members, including chairman, if minimum ownership or management agreements persist.","Co also to enter Strategic Advisor and Asset Management agreements with affiliates to manage digital assets and treasury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149249,"accession_number":"0001437749-25-022112","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Windtree raises $253,333 via convertible notes and warrants to fund operations","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued convertible notes with 14% annual interest and 12-month maturity; conversion price $0.587/share.","Warrants issued for 25% of purchase price at exercise price $1.10/share; total gross proceeds $253,333.","Proceeds to be used for operational expenses, including a loan to Titan Environmental Services, Inc.","Notes and warrants sold in unregistered transactions under Section 4(a)(2) and Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168279,"accession_number":"0001437749-25-021453","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","1.02","3.02","5.02","9.01"],"status":"ready","headline":"Windtree terminates $3M earnest money real estate deal; CFO resigns; raises $150K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 24, 2025, Windtree terminated the Purchase Agreement for the Aubrey property; TBB CPD demands $3M earnest money; company disputes.","CFO Jamie McAndrew resigned effective June 25, 2025; no disagreement; CEO Jed Latkin assumes interim principal financial officer role.","Issued two convertible notes for $150K gross proceeds; 14% interest, 12-month maturity; conversion price $0.587; warrants for 75% of purchase price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168278,"accession_number":"0001437749-25-020949","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Windtree receives Nasdaq bid price deficiency letter; delisting risk if hearing not granted by June 25","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Windtree on June 18, 2025 that closing bid price has been below $1.00 for 30 consecutive days.","Company is ineligible for standard 180-day compliance period due to two reverse stock splits >250:1 over prior two years.","Windtree must request a hearing by June 25, 2025, or face suspension/delisting from Nasdaq.","Company intends to request a hearing; automatic stay of delisting pending hearing and any extension granted by Panel.","Common stock continues trading under symbol WINT; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168277,"accession_number":"0001437749-25-020048","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Windtree raises $3.9M via convertible notes; signs non-binding LOIs for Varian asset sale and Titan acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $3.1M from DFU convertible note and $800K from other investors; proceeds to retire Titan debt and fund operations.","Issued $6.6M senior note to Standard Waste Services, maturing Jan 2026 or upon Titan acquisition; $1.99M OID.","Signed non-binding LOI to acquire Titan for $35M in preferred stock plus $1.75M bridge loans; break-up fee $8M.","Signed non-binding LOI to sell Varian assets for up to $7M cash/shares plus milestones/royalties; options for $5M.","Received lease default notice for $159,800; also default on Aubrey Agreement risking $1.4M deposit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168276,"accession_number":"0001437749-25-017298","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Windtree Q1 operating loss $4.1M, cash through May 2025; pivots to revenue via real estate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss $4.1M vs $4.4M prior year; net loss $5.0M ($4.63/share) vs net income $10.2M in Q1 2024.","Cash and equivalents $1.2M at March 31, 2025; company believes funds operations only through May 2025.","Closed private placement of Series D convertible preferred for $2.6M gross proceeds in April/May 2025.","New strategy: secured right to buy a 436-unit multifamily property in Houston; signed supply agreement with Evofem for PHEXXI contraceptive gel.","Istaroxime cardiogenic shock study enrolled; interim analysis of first 20 subjects expected in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168275,"accession_number":"0001437749-25-013977","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Windtree to acquire 436-unit Houston multifamily property for ~$43M; issues Series D preferred for $2.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WINT LLC (subsidiary) assigned rights to buy property; advanced $1.4M earnest money to extend closing to May 23, 2025.","Purchase price ~$43M, funded by non-recourse mortgage and preferred stock; two 30-day extensions at $1M each.","Closed private placement of 3,125 Series D Convertible Preferred shares for gross proceeds of ~$2.5M; conversion price $1.368.","Series D pays 10% dividend (18% default), no voting rights, 4.99/9.99% beneficial ownership cap, and multiple redemption options.","Rental revenue expected to support therapeutic pipeline; actively seeking additional revenue-generating acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168274,"accession_number":"0001437749-25-013630","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Windtree raises $2.5M via Series D convertible preferred at $1.368/share conversion price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 3,125 Series D convertible preferred shares for aggregate gross proceeds of approximately $2.5 million.","Conversion price set at $1.368 per share; 10% annual dividend (18% upon trigger events).","Company will seek stockholder approval for common shares issuable upon conversion.","90-day restriction on further equity issuances; mandatory redemption of existing Series C preferred and notes from future equity line proceeds.","Registration rights agreement requires filing resale registration statement within 15 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168273,"accession_number":"0001437749-25-012376","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree Therapeutics director Craig Fraser resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Fraser resigned from the Board effective April 17, 2025.","Resignation was not due to any disagreement with management or company operations.","Board reduced from five to four members following Fraser's departure.","Fraser was not a member of any Board committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168272,"accession_number":"0001437749-25-011986","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.","Cash and equivalents $1.8M at Dec 31, 2024; raised ~$2.3M post-period, funding operations only through April 2025.","New corporate strategy: use equity to acquire small biotech firms with FDA-approved products; signed Evofem deal for PHEXXI distribution.","Positive Phase 2 SEISMiC Extension for istaroxime in early cardiogenic shock; SEISMiC C trial enrolling, interim data in Q3 2025.","R&D spend rose to $16.3M from $8.3M, driven by $7.5M Varian IPR&D charge and increased istaroxime development costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168271,"accession_number":"0001437749-25-011690","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Windtree Therapeutics issues $312.5K in senior secured convertible notes at 20% OID for net proceeds of $250K","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $312,500 with 20% OID; net proceeds $250,000 from two institutional investors.","Notes mature Jan 4, 2026; 10% interest payable monthly; mandatory prepayment of 25% of gross proceeds from future common stock purchase agreement with 120% premium.","Conversion price $1.10 per share; anti-dilution adjustment if subsequent equity sales at lower price.","Company must file registration statement on Form S-1 for resale of conversion shares within 20 days.","Events of Default trigger additional interest of 2% per month (24% per annum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185460,"accession_number":"0001437749-25-009203","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K/A","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Windtree signs sourcing deal for Evofem's FDA-approved PHEXXI contraceptive gel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License and Supply Agreement makes Windtree sourcing partner for Evofem's PHEXXI (hormone-free vaginal gel).","PHEXXI generated >$19M revenue in FY2024; 96,000 boxes of 12 applicators sold.","Windtree aims to cut manufacturing costs via its contacts, aiding Evofem's global expansion.","Saundra Pelletier is CEO of Evofem and also serves on Windtree's board of directors.","Deal is first step in Windtree's new strategy to become a revenue-generating biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185466,"accession_number":"0001437749-25-008981","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Windtree raises $250K via secured notes, licenses Phexxi supply rights, regains Nasdaq compliance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $312,500 principal in senior secured notes at 10% interest, due March 2026, with 20% OID; net proceeds $250,000.","Entered license and supply agreement with Evofem to manufacture and supply Phexxi outside the U.S. for an initial three-year term.","Regained compliance with Nasdaq minimum bid price rule (closing bid >$1.00 since Feb 21, 2025); subject to panel monitor until March 20, 2026.","Notes secured by first-priority lien on all assets; mandatory redemption of 30% of equity line proceeds if equity line is used."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185465,"accession_number":"0001437749-25-004124","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Windtree Therapeutics announces 1-for-50 reverse stock split effective Feb 20, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved by stockholders on Feb 3, 2025; ratio set at 1-for-50.","Effective at 5:00 p.m. ET on Feb 20, 2025; adjusted trading begins Feb 21 under ticker WINT.","Aimed at meeting Nasdaq $1.00 minimum bid price requirement; new CUSIP: 97382D600.","Post-split outstanding shares reduced to approximately 700,000; no fractional shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185459,"accession_number":"0001437749-25-004055","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K/A","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","8.01","3.02"],"status":"ready","headline":"Windtree converts Series C Preferred to common at $0.1608, issuers 11.8M shares; holders grant forbearance.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 1,895 Series C Preferred shares converted into 11,792,305 common shares at reduced conversion price of $0.1608.","Holders agreed to forbearance on claims under securities purchase agreements and warrants through April 30, 2025.","Exercise price of related warrants also reduced to $0.1608 effective January 24, 2025.","Conversion was effected via a Conversion Notice signed by holders by Jan 31, 2025; exempt from registration under Section 3(a)(9) and 4(a)(2).","Company had previously registered up to 27,668,106 shares for resale on Form S-3 effective Sep 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185464,"accession_number":"0001437749-25-002624","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Windtree shareholders approve reverse stock split, reject equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved (ratio 1:5 to 1:50, board discretion) with 2,504,535 for, 1,752,258 against.","Equity plan amendment to increase shares from 41,010 to 1,141,010 failed: 586,282 for, 1,323,734 against, 2,381,134 broker non-votes.","Special meeting held Feb 3, 2025; record date Dec 20, 2024 with 11,048,828 shares outstanding.","Management loses ability to grant additional equity incentives under the 2020 Plan after rejection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185463,"accession_number":"0001437749-25-001922","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Windtree offers to cut Series C conversion price to $0.1608, seeks forbearance on claims until April 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company offered Series C preferred holders conversion price cut to $0.1608; accept by Jan 31, 2025.","Holders signing conversion notice agree to forbear from claims under purchase agreements and related docs through April 30, 2025.","There is no guarantee that any or all holders will accept the offer; conversion and issuance exempt from SEC registration.","Company previously registered resale of up to 27,668,106 shares issuable upon conversion of Series C and exercise of warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185462,"accession_number":"0001437749-25-000930","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Windtree appoints Leanne Kelly to board; launches strategy to acquire small biotechs with equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leanne Kelly appointed as independent director and Audit Committee chair effective Jan 8, 2025.","CEO states new corporate strategy: use equity to acquire small biotechs with FDA-approved products to become revenue-generating.","Company received Nasdaq deficiency notice Dec 4, 2024 for independent director/audit committee; expects Kelly's appointment to resolve.","Kelly is currently CFO of GRI Bio, with over 20 years of public company experience in life sciences and accounting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185461,"accession_number":"0001437749-25-000675","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Windtree shifts strategy to acquire FDA-approved product companies via all-stock deals","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New corporate strategy targets acquisition of small companies with FDA-approved products using equity.","Management aims to leverage commercialization expertise across large pharma and biotech to optimize acquired assets.","Company will continue advancing its cardiovascular and oncology pipeline alongside revenue-generating acquisitions.","CEO Jed Latkin says strategy marks a new chapter focused on near-term revenue and shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202052,"accession_number":"0001437749-24-036752","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Windtree receives Nasdaq delisting notices for board independence and bid price deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CEO appointment Jed Latkin (former independent director) on Dec 1, 2024 caused loss of majority independent board and audit committee shortfall.","Non-compliance with Nasdaq Rules 5605(b)(1) and 5605(c)(2)(A); cure period until Dec 1, 2025 or next annual meeting.","Bid price deficiency: closing bid below $1.00 for 30 consecutive days; ineligible for 180-day grace due to two reverse stock splits (cumulative >250:1) in prior 2 years.","Company intends to request a hearing before Nasdaq Hearings Panel to stay delisting; no assurance of regaining compliance.","Common stock continues trading on Nasdaq under symbol WINT; delisting risk remains if compliance not restored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202051,"accession_number":"0001437749-24-036647","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.","Company cites positive Phase 2b SEISMiC study in early cardiogenic shock as catalyst for potential non-dilutive partnership.","Existing Lee's Pharmaceuticals deal offers up to $138M in milestones plus low double-digit royalties for Greater China.","NGA has advised on transactions with aggregate value approaching $400M from 2023 through 2024.","Proceeds from any deal would support advancement of Windtree's novel preclinical oncology platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202050,"accession_number":"0001437749-24-036346","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Windtree reports Q3 net loss $3.8M; cash runway only through Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss $4.7M flat vs Q3 2023; net loss $3.8M ($4.23/share) vs $4.4M ($15.47/share) a year ago.","Cash $2.3M at Sep 30; subsequent ELOC sales raised $2.4M net; funds only through January 2025.","Positive Phase 2b istaroxime data in early cardiogenic shock: primary SBP AUC endpoint met; safety favorable.","July 2024 private placements raised ~$13.9M aggregate ($4.4M new cash, $9.5M debt conversion); $35M ELOC secured.","Nasdaq non-compliance for late 10-Q resolved after filing on Nov 26; listing compliance restored Nov 27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202044,"accession_number":"0001437749-24-035497","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K/A","filed_at":"2024-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree Therapeutics finalizes CFO Jamie McAndrew's employment agreement; base salary $370K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement finalized Nov 8, 2024; annual base salary $370,000.","Eligible for year-end bonus target 40% of base salary, at Compensation Committee discretion.","Termination without cause or for good reason: 12 months base salary severance, pro-rata bonus, COBRA.","Change of control: 1.5x (base + target bonus) lump sum, full equity acceleration, 18 months COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202049,"accession_number":"0001437749-24-035033","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree CEO Craig Fraser retires; Jed Latkin appointed President & CEO effective Dec 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craig Fraser retires as President and CEO effective Dec 1, 2024, but remains Chairman of the Board.","Jed Latkin, age 50, appointed President and CEO; previously COO and CFO of ProPhase Labs.","Latkin's base salary set at $557,300, with target annual bonus of 50% of base salary.","Latkin eligible for equity award of 2.5% of outstanding shares, subject to shareholder approval.","Employment agreement includes 12-month non-compete and severance benefits for termination without cause or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202048,"accession_number":"0001437749-24-032316","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Windtree files prospectus supplement for up to $27.2M stock issuance to Seven Knots","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered up to $27,243,504 in common shares for issuance and resale under existing equity line with Seven Knots.","As of Oct 25, 2024, issued 5,499,273 shares for $7,756,496 gross proceeds under the Purchase Agreement.","Redeemed 1,499 Series C Preferred Shares for $2.3M using proceeds from equity line sales.","Obtained stockholder approval at Sept 2024 annual meeting to exceed the Nasdaq Exchange Cap.","Based on 8,746,128 shares outstanding, no longer subject to Form S-3 one-third float limit until next 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202047,"accession_number":"0001437749-24-030737","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Windtree Therapeutics share count more than doubles to 3.68M in three weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["From Sep 14 to Oct 4, sold 790,500 shares via ELOC for $1.7M gross proceeds.","Converted 2,368 Series C Preferred Shares into 1,278,452 common shares.","Redeemed 611 Preferred Shares for $0.8M aggregate redemption price.","Outstanding shares increased from 1,610,734 (Sep 13) to 3,679,686 (Oct 4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202046,"accession_number":"0001437749-24-030379","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Windtree appoints Jamie McAndrew as CFO effective September 25, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jamie McAndrew, 44, appointed SVP and CFO; had been VP, Controller, and CAO since August 2023.","Annual base salary increased to $370,000; employment agreement terms pending further amendment.","McAndrew joined Windtree in 2013 as Manager of Accounting and Reporting; prior experience at KPMG.","No family relationships or related-party transactions with McAndrew requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202045,"accession_number":"0001437749-24-030303","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Windtree updates investor slide deck for meetings; no financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated investor presentation dated October 1, 2024.","Presentation to be used in meetings with investors; no new financial or operational data provided.","No material changes or specific figures were included in the exhibit text available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218093,"accession_number":"0001437749-24-030219","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: istaroxime significantly improved systolic blood pressure (SBP AUC) vs placebo (p=0.0070) in combined Part A/B analysis.","Istaroxime improved cardiac output by ~15%, reduced heart rate, and lowered pulmonary capillary wedge pressure (PCWP) vs placebo at multiple timepoints.","Renal function (eGFR) improved with istaroxime at 48 hours (p=0.0291); NYHA heart failure classification improved through 72 hours.","Serious adverse events were similar: 10.5% istaroxime vs 27.3% placebo; no increase in clinically significant arrythmias observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218092,"accession_number":"0001437749-24-029936","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Windtree announces positive Phase 2b topline results for istaroxime in early cardiogenic shock","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Istaroxime met primary endpoint: significantly improved systolic blood pressure profile over six hours vs placebo.","Significant improvements in many secondary endpoints; safety profile favorable, consistent with prior trials.","Study tested two dosing regimens (decreasing and constant) over up to 60 hours infusion to optimize late-stage design.","Detailed results to be presented at Heart Failure Society of America on Sept 30, 2024; investor call planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218091,"accession_number":"0001437749-24-029915","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Windtree shareholders approve all proposals at annual meeting, including equity issuances","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Fraser, Latkin, Pelletier, Strobeck with >258,000 votes each; broker non-votes 112,534.","Advisory say-on-pay approved: 252,693 for, 11,061 against, 8,795 abstentions, 112,534 broker non-votes.","Ratified EisnerAmper as 2024 auditor: 368,203 for, 7,737 against, 9,143 abstentions (no broker non-votes).","Approved share issuance under committed equity financing (255,211 for, 8,648 against) per Nasdaq Rule 5635(d).","Approved conversion of Series C Preferred (initial conv. price $3.74, floor $1.28) and warrant exercise ($4.11): 251,535 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218090,"accession_number":"0001437749-24-029169","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Windtree Therapeutics updates equity transactions: sold 949,948 shares for $3.2M, shares outstanding tripled to 1.61M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 949,948 common shares under ELOC for ~$3.2M gross proceeds as of Sep 13, 2024.","Converted 202.5 Series C Preferred Shares into 68,877 common shares; redeemed 191.5 Preferred Shares for $0.4M.","Shares outstanding rose from 591,909 (Jun 30) to 1,610,734 (Sep 13).","Registration statements for private placement and ELOC became effective Sep 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218089,"accession_number":"0001437749-24-027380","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.","R&D expense $9.9M (incl. $7.5M non-cash Varian asset acquisition cost) vs. $1.8M; G&A $1.6M vs. $2.4M.","Cash $1.8M, current liabilities $8.8M; substantial doubt about going concern disclosed.","Closed July transactions for $13.9M gross proceeds ($4.4M new funding, $9.5M note extinguishment); $35M equity line secured.","Istaroxime Phase 2 SEISMiC study enrollment near complete, topline by end of Q3 2024; board added Saundra Pelletier, Jed Latkin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218088,"accession_number":"0001437749-24-026816","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Windtree Therapeutics board reshuffled: two directors exit, two appointed, lead independent director named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Geffken and Leslie J. Williams resigned from the Board August 13, 2024; no disagreement with company.","Board appointed Jed Latkin and Saundra Pelletier as directors; Latkin chairs Audit, Pelletier chairs Compensation.","Mark Strobeck, Ph.D., appointed lead independent director effective August 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218087,"accession_number":"0001437749-24-023668","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Windtree raises ~$1.0M via Series C preferred stock and warrants; exercise price $4.11","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,250 Series C Convertible Preferred Shares and warrants for 267,380 common shares.","Gross proceeds of approximately $1.0 million; expected closing July 29, 2024.","Warrants exercisable at $4.11 per share, six-month lockout, expire five years after.","Proceeds for working capital; stockholder approval needed for conversion shares.","Registration rights agreement to file resale registration statement within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218086,"accession_number":"0001437749-24-023137","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","5.03","1.02","3.02","3.03","9.01"],"status":"ready","headline":"Windtree Therapeutics raises $12.9M via Series C Preferred and Warrants; cancels $9.5M debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$12.9M from private placement of Series C Convertible Preferred Stock and warrants; $9.5M used to cancel existing convertible notes, secured notes, and Series B preferred shares.","Series C Preferred has stated value $1,000/share, initial conversion price $3.74, convertible into 267 shares of common; 10% dividend rate (18% default).","Warrants to purchase up to 3,440,631 shares of common at $4.11/share, exercisable starting 6 months + 1 day after issuance, expiring 5 years later.","Company issues 161 Preferred Shares and 42,838 Warrants as placement agent compensation.","Company agrees to seek stockholder approval for share issuance; restricted period of 90 trading days with no further equity-linked issuances without consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218085,"accession_number":"0001437749-24-022492","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Windtree Therapeutics issues $200K in senior secured/unsecured notes due 2025 at 10% interest with 15% OID","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $117,647 secured note and $117,647 unsecured promissory note for $200K gross proceeds; 15% original issue discount.","Notes bear 10% annual interest, increasing to 18% upon default; payable monthly in cash.","Maturity July 3, 2025, extendable at holder's option; optional redemption at 120% of remaining amount.","Mandatory redemption from 30% of proceeds if stock sold under equity line of credit.","Secured note has first-priority security interest in all present and after-acquired assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218084,"accession_number":"0001437749-24-022078","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Windtree Therapeutics updates investor presentation; no material financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated its investor slide presentation on July 3, 2024.","No specific financial results, guidance, or material events were included in the filing.","Presentation will be used in meetings with investors, but contents are not summarized.","No changes to business outlook, leadership, or strategy were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218083,"accession_number":"0001437749-24-021726","cik":946486,"company_name":"WINDTREE THERAPEUTICS INC /DE/","ticker":"WINT","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Windtree enters $35M equity line, issues $350K convertible note and $405K bridge notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common Stock Purchase Agreement with Seven Knots, LLC allows sales up to $35M (or 19.99% outstanding) over 36 months at up to 5% discount to VWAP.","Issued $350,000 convertible promissory note as commitment fee; 10% interest, convertible at 20% discount to lowest intraday price.","Issued $287,500 and $117,647 senior secured bridge notes (10% interest, 15% OID) for $350,000 aggregate net proceeds; mandatory redemption from equity line proceeds.","Equity line purchases require SEC registration effective and common stock price at or above $0.50; company controls timing and amount.","Company plans to use proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":660000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-07-01T23:59:59+00:00|218083"}